Targeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activity

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2412-2423

  Petty, Aaron P ^d   Wright, Stephen E ^a,b,c   Rewers Felkins, Kathleen A ^a,b   Yenderrozos, Michelle A ^d   Vorderstrasse, Beth A ^d   Lindsey, J Suzanne ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Harrington Cancer Center   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MATRIGEL; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN ANTIBODY; PROTEIN KINASE B; PROTEIN MIG 7; PROTEIN MIG 7 ANTIBODY; S6 KINASE; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER IMMUNOLOGY; CANCER INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; HUMANS; MATRIX METALLOPROTEINASE 14; MICE; MONOCYTES; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHOSPHORYLATION;

EID: 68849084310     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0186     Document Type: Article

References (53)

1. Condeelis J, Singer RH, Segall JE. The great escape: When cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol 2005;21:695-718.
2. Crouch S, Spidel CS, Lindsey JS. HGF and ligation of avb5 integrin induce a novel, cancer cell-specific gene expression required for cell scattering. Exp Cell Res 2004;292:274-87.
3. Petty AP, Garman KL, Winn VD, Spidel CM, Lindsey JS. Overexpression of carcinoma and embryonic cytotrophoblast cell-specific Mig-7 induces invasion and vessel-like structure formation. Am J Pathol 2007;170:1763-80.
4. Phillips TM, Lindsey JS. Carcinoma cell-specific Mig-7: a new potential marker for circulating and migrating cancer cells. Oncol Rep 2005;13:37-44.
5. Robertson GP. Mig-7 linked to vasculogenic mimicry. Am J Pathol 2007;170:1454-6.
6. Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin α v β 5 to promote tumor cell dissemination in vivo. J Clin Invest 1997;99:1390-8.
7. Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase signaling required for integrin α v β 5-directed cell motility but not adhesion on vitronectin. J Cell Biol 1994;127:859-66.
8. Beard J. Embryological aspects and etiology of carcinoma. Lancet 1902;1:1758-61.
9. Red-Horse K, Zhou Y, Genbacev O, et al. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest 2004;114:744-54.
10. Soundararajan R, Rao AJ. Trophoblast 'pseudo-tumorigenesis': significance and contributory factors. Reprod Biol Endocrinol 2004;2:15.
11. Seftor REB, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 g2 chain, matrix metalloproteinase-2, and membrane type-1 matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001;61:6322-7.
12. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol 1999;155:739-52.
13. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001;158:1279-88.
14. Sun B, Zhang S, Zhang D, et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006;16:693-8.
15. van der Schaft DWJ, Hillen F, Pauwels P, et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 2005;65:11520-8.
16. Hendrix MJC, Seftor EA, Kirschmann DA, Quaranta V, Seftor REB. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann NY Acad Sci 2003;995:151-61.
17. Koshikawa N, Minegishi T, Sharabi A, Quaranta V, Seiki M. Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin {γ}2 chain. J Biol Chem 2005;280:88-93.
18. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000;148:615-24.
19. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45.
20. Petty AP, Dick CL, Lindsey JS. Translation of an atypical human cDNA requires fidelity of a purine-pyrimidine repeat region and recoding. GENE 2008;414:49-59.
21. Wright SE, Kilinski L, Talib S, et al. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother 2000;23:2-10.
22. Hendrix MJC, Seftor EA, Seftor REB. Comparison of tumor cell invasion assays: human amnion versus reconstituted basement membrane barriers. Invasion Metastasis 1989;9:278-97.
23. Yang AD, Camp ER, Fan F, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006;66:46-51.
24. Noguchi P. Use of flow cytometry for DNA analysis. In: Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W, editors. Current Protocols in Immunology. New York: Wiley-Interscience; 1991, p. 5.7.1-5.7.4.
25. Windsor LJ, Bodden MK, Birkedal-Hansen B, Engler JA, Birkedal-Hansen H. Mutational analysis of residues in and around the active site of human fibroblast-type collagenase. J Biol Chem 1994;269:26201-7.
26. Williams NS, Burgett AWG, Atkins AS, Wang X, Harran PG, McKnight SL. Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity. Proc Natl Acad Sci U S A 2007;104:2074-9.
27. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991;142:257-65.
28. Bae-Jump V, Segreti EM, Vandermolen D, Kauma S. Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol Oncol 1999;73:265-72.
29. Bescond A, Augier T, Chareyre C, Garcon D, Hornebeck W, Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999;263:498-503.
30. Wart HEV, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990;87:5578-82.
31. Birkedal-Hansen H, Taylor RE. Detergent-activation of latent collagenase and resolution of its component molecules. Biochem Biophys Res Commun 1982;107:1173-8.
32. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med 2002;9:401-4.
33. Rozanov DV, Deryugina EI, Ratnikov BI, et al. Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys574, the active site Glu240, and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells. J Biol Chem 2001;276:25705-14.
34. Doerr ME, Jones JI. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 1996;271:2443-7.
35. Silvestri I, Cattani IL, Franco P, et al. Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating avb5 vitronectin receptor cell surface expression. Int J Cancer 2002;102:562-71.
36. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998;70:1-81.
37. Celis JE, Moreira JMA, Gromova I, et al. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol 2007;1:97-119.
38. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
39. Lehti K, Lohi J, Valtanen H, Keski-Oja J. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J 1998;334:345-53.
40. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
41. Gingras D, Bousquet-Gagnon N, Langlois S, Lachambre M-P, Annabi B, Béliveau R. Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). FEBS Lett 2001;507:231-6.
42. D'Alessio S, Ferrari G, Cinnante K, et al. Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem 2008;283:87-99.
43. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 2007;67:3626-36.
44. Hollier BG, Kricker JA, Van Lonkhuyzen DR, Leavesley DI, Upton Z. Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-kinase/AKT pathway by {α}v-integrins and the IGF-I receptor. Endocrinology 2008;149:1075-90.
45. Matsuo M, Sakurai H, Ueno Y, Ohtani O, Saiki I. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin αv-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Cancer Sci 2006;97:155-62.
46. Zhou HY, Pon YL, Wong AST. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology 2007;148:5195-208.
47. Wong AST, Roskelley CD, Pelech S, Miller D, Leung PCK, Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res 2004;299:248-56.
48. Lehti K, Allen E, Birkedal-Hansen H, et al. An MT1-MMP-PDGF receptor-{β} axis regulates mural cell investment of the microvasculature. Genes Dev 2005;19:979-91.
49. Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M, Sato H. Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res 2004;64:1044-9.
50. Tsubaki M, Matsuoka H, Yamamoto C, et al. The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2. Clin Exp Metastasis 2007;24:431-8.
51. Bonta IL, Ben Efraim S. Interactions between inflammatory mediators in expression of antitumor cytostatic activity of macrophages. Immunol Lett 1990;25:295-301.
52. Xiang J, Moyana T, Qi Y. Genetic engineering of a recombinant fusion possessing anti-tumor F(ab′)2 and tumor necrosis factor. J Biotechnol 1997;53:3-12.
53. Nyalendo C, Beaulieu E, Sartelet H, et al. Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis 2008;29:1655-64.